Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase 2 MOONLIGHT-1 study in major depressive disorder (MDD).
READ ALSO: Can Oral Wegovy Help Novo Nordisk Capture China’s $4.46 Billion GLP-1 Opportunity?
For investors, attention now turns to Johnson & Johnson’s (NYSE:JNJ) review of the remaining study data and what that means for the future of the program.
Bull Case
There is little reason to put a positive spin on a missed primary endpoint. Still, the study did provide one favorable result on safety. Contineum said JNJ-5120/PIPE-307 was well tolerated and showed no new safety signals in the trial. That does not offset the efficacy failure, but it means the topline result did not identify a new safety issue alongside it. Johnson & Johnson also has not announced that development of the drug is ending. The company is continuing to analyze the broader dataset, including prespecified exploratory endpoints, before determining next steps. That leaves the program’s future unresolved rather than formally discontinued.
The MOONLIGHT-1 study enrolled 107 adults with MDD and evaluated JNJ-5120/PIPE-307 as a monotherapy. Its primary endpoint measured the change from baseline in the Montgomery-Åsberg Depression Rating Scale, or MADRS, total score at Day 5 compared with placebo. The five-day endpoint reflected one of the ideas behind the program, which was how JNJ-5120/PIPE-307 targets the muscarinic M1 receptor and was being evaluated as a potential rapidly acting treatment for depression.
DON’T MISS: Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?
For Contineum shareholders, there is also an important distinction between this program and the rest of the company’s pipeline. Johnson & Johnson is responsible for developing JNJ-5120/PIPE-307 under the companies’ global agreement, while Contineum continues to advance its internally developed PIPE-791 program in other indications.
Bear Case
The central problem in this context for investors is straightforwardly that JNJ-5120/PIPE-307 did not demonstrate the efficacy required by the Phase 2 trial’s primary endpoint. That result is particularly significant because the trial was designed as a proof-of-concept study in MDD. The primary endpoint specifically tested whether the drug could improve MADRS scores at Day 5 relative to placebo, and it did not meet that threshold.
It is also not the first disappointing efficacy result for PIPE-307, as in 2025, a study evaluating the same compound in patients with relapsing-remitting multiple sclerosis failed to demonstrate a benefit on its primary efficacy measure. The latest MDD result therefore gives investors another negative clinical readout involving the same drug, albeit in a different disease and study design.
Johnson & Johnson’s (NYSE:JNJ) continuing analysis of exploratory endpoints may provide additional information about the drug, but those analyses should not be confused with the study’s prespecified primary efficacy result, as the primary endpoint was missed.
Conclusion
For Contineum investors, the most important fact is also the simplest one, which is that PIPE-307 has now missed the primary efficacy goal of its Phase 2 depression study. The absence of new safety signals and Johnson & Johnson’s continuing review of the broader dataset leave the program alive for now, but they do not change the topline efficacy result. Any further case for JNJ-5120/PIPE-307 will have to come from the additional data J&J is still analyzing and whatever development decision follows.
There is also a broader distinction worth keeping in mind. PIPE-307 is partnered with Johnson & Johnson, while Contineum continues to develop PIPE-791 in programs including idiopathic pulmonary fibrosis and chronic pain. That makes J&J’s next decision on PIPE-307 important, but it is not the only clinical program determining Contineum’s future. For now, the next concrete milestone is J&J’s decision on what, if anything, comes next for JNJ-5120/PIPE-307.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
